Compare CCSI & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCSI | DSGN |
|---|---|---|
| Founded | 2021 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 549.8M | 528.1M |
| IPO Year | N/A | 2021 |
| Metric | CCSI | DSGN |
|---|---|---|
| Price | $23.73 | $9.11 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $29.00 | $13.50 |
| AVG Volume (30 Days) | 173.2K | ★ 335.0K |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.22 | N/A |
| Revenue | ★ $349,609,000.00 | N/A |
| Revenue This Year | $1.67 | N/A |
| Revenue Next Year | $0.97 | N/A |
| P/E Ratio | $5.67 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.84 | $2.60 |
| 52 Week High | $32.10 | $10.31 |
| Indicator | CCSI | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 52.73 | 57.87 |
| Support Level | $21.92 | $9.00 |
| Resistance Level | $23.14 | $9.67 |
| Average True Range (ATR) | 0.79 | 0.67 |
| MACD | 0.39 | -0.08 |
| Stochastic Oscillator | 83.79 | 46.28 |
Consensus Cloud Solutions Inc is a provider of secure information delivery services with a scalable Software-as-a-Service SaaS platform. It is engaged in fax cloud business. The Company operates in USA, Canada, Ireland, and Other. Geographically, it derives a maximum revenue from the United States. The company's communication and digital signature solutions enable customers to securely and cooperatively access, exchange and use information across organizational, regional, and national boundaries.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.